Horizon scanning is the process which allows the identification of new
and emerging medical products via systematic analysis of pipeline health
technologies, typically before both market entry and the HTA process. Early
identification of new medicines enables assessment of their potential relevance
and impact on the healthcare system, besides the identification of possible
threats and opportunities, thus allowing for pro-active policymaking and better
budgetary planning.
A horizon scanning system was established within the Pharmaceutical
Policy and EU Affairs Unit in 2020 with the aim of performing horizon scanning
activities within the context of pharmaceutical policy. The horizon scanning
system at DPA aims to improve strategic financial planning and decision-making
by providing early intelligence on new medicines which are not yet
licensed.
For further information please contact us on dpa.strategyandpolicy@gov.mt